Abstract:As a single receptor, the neonatal Fc receptor (FcRn) is critically involved in regulating albumin and IgG serum concentrations by protecting these two ligands from degradation. In addition to these essential homeostatic functions, FcRn possesses important functions in regulating immune responses that are equally as critical and are increasingly coming to attention. During the first stages of life, FcRn mediates the passive transfer of IgG across the maternal placenta or neonatal intestinal walls of mammals, thereby conferring passive immunity to the offspring before and after birth. In fact, FcRn is one of the very few molecules that are known to move from luminal to serosal membranes of polarized cells that form epithelial barriers of the lung and intestines. Together with FcRn's recently explored critical role in eliciting MHC II presentation and MHC class I cross-presentation of IgG-complexed antigen, this renders FcRn capable of exerting broad and potent functions in regulating immune responses and immunosurveillance at mucosal sites. Further, it is now clear that FcRn dependent mucosal absorption of therapeutic molecules is a clinically feasible and potent novel route of non-invasive drug delivery, and the interaction between FcRn and IgG has also been utilized for the acquisition of humoral immunity at mucosal sites. In this review, we begin by briefly summarizing the basic knowledge on FcRn expression and IgG binding, then describe more recent discoveries pertaining to the mechanisms by which FcRn orchestrates IgG related mucosal immune responses and immunosurveillance at host-environment interfaces within the adult organism. Finally, we outline how the knowledge of actions of FcRn at mucosal boundaries can be capitalized for the development and engineering of powerful mucosal vaccination strategies and novel routes for the non-invasive delivery of Fc-based therapeutics.

Update on Fc receptor-like (FCRL) family: new immunoregulatory players in health and diseases

Roles for the FCRL6 Immunoreceptor in Tumor Immunology

The potential of FCRL genes as targets for cancer treatment: insights from bioinformatics and immunology

Fc Receptor Targeting in the Treatment of Allergy, Autoimmune Diseases and Cancer

Understanding Fc Receptor Involvement in Inflammatory Diseases: From Mechanisms to New Therapeutic Tools

Fc receptor-like 6 (FCRL6) delineates innate-like B cell progenitors that undergo pre-BCR dependent and independent pathways of natural antibody selection

Fc gamma receptors: Their evolution, genomic architecture, genetic variation, and impact on human disease

Fc receptor-like 6 (FCRL6) defines pre-BCR dependent and independent pathways of natural antibody selection

FCRL6 distinguishes a subset of biologically impaired mouse pro B cells (153.16)

Fc receptors and their role in immune regulation and autoimmunity

Fc Receptor-Like 6 (FCRL6) Discloses Progenitor B Cell Heterogeneity That Correlates With Pre-BCR Dependent and Independent Pathways of Natural Antibody Selection

Expression of Fc Fragment Receptors of Immunoglobulin G (fcγrs) in Rat Hepatic Stellate Cells

Defining the Immunological Phenotype of Fc Receptor-Like B (FCRLB) Deficient Mice: Confounding Role of the Inhibitory FcγRIIb.

Cutting Edge: FcR-Like 6 Is an MHC Class II Receptor

Regulation of B‐cell function and expression of CD11c, T‐bet, and FcRL5 in response to different activation signals

Regulation of immune responses by the neonatal fc receptor and its therapeutic implications

Current development of Fc gamma receptors (FcγRs) in diagnostics: a review

Antibody-Targeted TNFRSF Activation for Cancer Immunotherapy: the Role of FcRIIB Cross-Linking

Systematic identification of genomic elements that regulate FCGR2A expression and harbor variants linked with autoimmune disease

Fc Receptor–like 1 Intrinsically Recruits C-Abl to Enhance B Cell Activation and Function

The era of the immunoglobulin A Fc receptor FcαRI; its function and potential as target in disease